LPL and metabolic syndrome: Correspondingly, elevated betatrophin levels may contribute toward the pathogenesis of dyslipidemia, which is one of the most important risk factors for CAD, while in vitro and in vivo studies have suggested that ﻿betatrophin could aggravate hypertriglyceridemia by promoting the ability of ANGPTL3 to bind and inhibit LPL [5, 6, 35].